LAUSR

641 1. Maltseva N, Borzova E, Fomina D, et al. Cold urticaria What we know and what we do not know. Allergy 2021; 76: 1077-94. 2. EMA. Xolair. European Medicines Agency, 2018. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/xolair [accessed on 09/03/2022]. 3. Baiardini I, Pasquali M, Braido F, et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL). Allergy 2005; 60: 1073-8. 4. Metz M, Schütz A, Weller K, et al. Omalizumab is effective in cold urticaria-results of a randomized placebo-controlled trial. J Allergy Clin Immunol 2017; 14: 864-7. 5. Maurer M, Metz M, Brehler R, et al. Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence. J Allergy Clin Immunol 2018; 141: 638-49. 6. Kulthanan K, Hunnangkul S, Tuchinda P, et al. Treatments of cold urticaria: a systematic review. J Allergy Clin Immunol 2019; 143: 1311-31. 7. Bizjak M, Košnik M, Terhorst-Molawi D, et al. Agglutinins and cryoglobulins associate with clinical and laboratory parameters of cold urticaria. Front Immunol 2021; 12: 665491. 8. Comarmond C, Cacoub P, Saadoun D. Treatment of chronic hepatitis C-associated cryoglobulinemia vasculitis at the era of direct-acting antivirals. Therap Adv Gastroenterol 2020; 13: 1756284820942617. 9. Dammacco F, Lauletta G, Russi S, et al. Clinical practice: hepatitis C virus infection, cryoglobulinemia and cryoglobulinemic vasculitis. Clin Exp Med 2019; 19: 1-21. 10. Mazzaro C, Maso LD, Mauro E, et al. Survival and prognostic factors in mixed cryoglobulinemia: data from 246 cases. Diseases 2018; 6: E35.